Vertex’s VX-548 For Acute Pain May Be Right On Time For Market

Medicare Policy Change In 2025 Favors Non-Opioids

 
• By Mandy Jackson

The company’s NaV1.8 inhibitor succeeded in Phase III acute pain trials and will be submitted for US FDA approval in mid-2024. It may reach the market in time for Medicare reimbursement changes favoring non-opioids.

Abdominoplasty plastic operation to reduce the abdomen and remove cellulite
VX-548 succeeded in Phase III abdominoplasty and bunionectomy studies • Source: Shutterstock

More from Clinical Trials

More from R&D